CCDM Dumps with Practice Exam Questions Answers

When a system validation test fails duringElectronic Patient-Reported Outcome (ePRO)system testing, thevalidation documentationmust record theexpected results(what should have occurred) and theactual results(what occurred).

According to theGCDMP (Chapter: Database Validation and Testing), proper system validation documentation ensurestraceability, reproducibility, and compliancewithFDA 21 CFR Part 11andICH E6 (R2). Each test case must include:

Test objective,

Preconditions,

Test steps,

Expected results,

Actual results, and

Pass/fail status.

If a test fails, this documentation provides the objective evidence necessary for deviation handling, issue resolution, and re-testing. While a separateroot cause analysismay be performed later (option D), the validation record itself must focus on verifying outcomes against predefined expectations.

Therefore, the correct answer isB – Expected and actual results.

Reference (CCDM-Verified Sources):

SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Database Validation and Testing, Section 4.4 – Documentation of Test Results

FDA 21 CFR Part 11 – Validation Requirements (Section 11.10(a))

ICH E6 (R2) GCP, Section 5.5.3 – Computer System Validation and Documentation

To properly associatebody-composition data(from a DEXA scanner) with other study data, both thesubject numberand thevisit numberare required.

According to theGCDMP (Chapter: Data Management Planning and Study Start-up), every clinical data record must beuniquely identifiable and linkableto a specific subject and study event. Thesubject numberidentifies the participant, while thevisit numberdefines the temporal context in which the measurement was taken.

Without both identifiers, data integration becomes ambiguous—especially if multiple assessments occur over time (e.g., baseline, week 12, end of study). Including both ensuresdata traceability, integrity, and alignmentwith the protocol-defined schedule of events.

Study number (option A) alone does not distinguish between visits or subjects, and visit number alone (option C) lacks linkage to the individual participant.

Reference (CCDM-Verified Sources):

SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Data Management Planning and Study Start-up, Section 4.4 – Data Linking and Identification Requirements

ICH E6 (R2) GCP, Section 5.5.3 – Data Traceability Principles

FDA Guidance for Industry: Computerized Systems Used in Clinical Investigations – Data Identification Requirements

UnderFDA 21 CFR Part 11, organizations using electronic systems must ensure thatall system users are trainedto perform their assigned functions before gaining access to the system. The regulation requires documented evidence of training but does not specify how it should be conducted (e.g., exam-based, in person, or language-specific).

TheGCDMP (Chapter: Computerized Systems and Compliance)further clarifies that personnel training should include instruction onsystem functionality, audit trails, data entry procedures, and electronic signaturesto maintain compliance and data integrity. Training must beperformed and documentedbut does not require a specific format or delivery method.

Therefore,option A—Training must be performed—is correct, as it reflects theminimum regulatory expectationper FDA and SCDM standards.

Reference (CCDM-Verified Sources):

FDA 21 CFR Part 11, Section 11.10(i) – Personnel Training Requirements

SCDM GCDMP, Chapter: Computerized Systems and Compliance, Section 5.4 – System Training and Documentation

ICH E6(R2) GCP, Section 2.8 – Qualified Personnel and Training Requirements

The best response is thatdiary data to be source data verified should be selected using a risk-based approach.

According to theGCDMP (Chapter: Data Quality Assurance and Control)andFDA Guidance on Risk-Based Monitoring (RBM), not all data require full SDV. Electronic patient-reported outcome (ePRO) or mobile diary data are typicallydirect electronic source data (eSource)captured at the time of entry, which already ensures authenticity and traceability.

Arisk-based SDV approachfocuses verification efforts on data critical tosubject safety and primary efficacy endpoints, as defined in the study’sRisk Assessment PlanorMonitoring Plan. Random or full verification of low-risk data (like diary compliance metrics) adds unnecessary effort and cost.

Thus,Option Caligns with current regulatory expectations and data management best practices.

Reference (CCDM-Verified Sources):

SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Data Quality Assurance and Control, Section 7.3 – Risk-Based Monitoring and SDV

ICH E6 (R2) Good Clinical Practice, Section 5.18 – Risk-Based Quality Management

FDA Guidance for Industry: Oversight of Clinical Investigations — A Risk-Based Approach to Monitoring (2013)

Thebest practicefor developingelectronic Case Report Forms (eCRFs)is to involvecross-functional team membersthroughout the design process.

According to theGCDMP (Chapter: CRF Design and Data Collection), eCRFs should be collaboratively developed bydata management, clinical operations, biostatistics, medical, and regulatory teams. Each function provides a unique perspective — data managers focus on data capture and validation; statisticians ensure alignment with analysis requirements; clinicians ensure medical relevance and protocol compliance.

Collaborative development ensures that the eCRFs arefit-for-purpose, capturing all required data accurately, minimizing redundancy, and supporting downstream data analysis.

Options A and B violate good data management practice because sites should not directly access coded terms (to prevent bias), and fields shouldnever auto-populate without explicit source verification. Option D is outdated; while paper CRFs may inform structure,EDC-optimized eCRFsshould leverage system functionality rather than mimic paper.

Reference (CCDM-Verified Sources):

SCDM Good Clinical Data Management Practices (GCDMP), Chapter: CRF Design and Data Collection, Section 4.2 – Collaborative CRF Development

ICH E6 (R2) GCP, Section 5.5.3 – Data Collection and System Validation

FDA Guidance for Industry: Electronic Source Data in Clinical Investigations, Section 3.4 – CRF Design Considerations